RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06938 RIBOLIFE-B

Not Yet Opened 02-25 16:08:33

71.500

+0.000

0.00%

High71.600	Low70.400	Vol86.50K
Open71.000	D1 Closing71.500	Amplitude1.68%
Mkt Cap12.19B	Tradable Cap12.19B	Total Shares170.55M
T/O6.14M	T/O Rate0.05%	Tradable Shares170.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":71.5,"timestamp":1772006913645,"preClose":71.5,"halted":0,"volume":86500,"delay":0,"changeRate":0,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-25 16:08:33","open":71,"high":71.6,"low":70.4,"amount":6140245,"amplitude":0.016783,"askPrice":71.6,"askSize":200,"bidPrice":71.1,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772069400000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":71.5,"openAndCloseTimeList":[[1771983000000,1771992000000],[1771995600000,1772006400000]],"volumeRatio":0.5556939458327941,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938/tweets","defaultTab":"tweets","newsList":[{"id":"1188158344","title":"GTHT: Factor XI Drives New Era in Anticoagulant Therapy with Multi-Technological Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=1188158344","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188158344?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:58","pubTimestamp":1771999118,"startTime":"0","endTime":"0","summary":"Demographic aging and rising prevalence of cardiovascular diseases are driving continuous expansion in the antithrombotic drug market. Anticoagulants, as a core category, are experiencing steady...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU2543165471.USD","601211","BK0028","BK0184","BK0183","BK1564","01276","BK0276","LU1023057109.AUD","BK0201","BK1161","LU0359201885.HKD","BK1191","06938","BK0012","BK0188","LU0359202008.SGD","02611","BK1147"],"gpt_icon":0},{"id":"1160415519","title":"China International Capital Initiates Coverage on RIBOLIFE-B (06938) with \"Outperform\" Rating, Sets HK$100 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1160415519","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160415519?lang=en_us&edition=fundamental","pubTime":"2026-02-20 10:10","pubTimestamp":1771553430,"startTime":"0","endTime":"0","summary":"China International Capital issued a research report initiating coverage on RIBOLIFE-B (06938) with an \"Outperform\" rating. Based on a DCF valuation, the firm set a target price of HK$100.0, implying...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2612147185","title":"Suzhou Ribo's Swedish Clinical Team Likely Sets It Apart From Peers -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2612147185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612147185?lang=en_us&edition=fundamental","pubTime":"2026-02-19 12:32","pubTimestamp":1771475520,"startTime":"0","endTime":"0","summary":"0432 GMT - Suzhou Ribo Life Science's Swedish clinical team appears key to differentiating it from its Chinese pharmaceutical peers, say Macquarie Capital analysts in a note. The company's team in Sweden conducts proof-of-concept trials, which gives these trials global relevance and its clinical data credibility, they say. Ribo also has a broad drug pipeline and partnerships with global pharmaceutical corporates such as Boehringer Ingelheim and Madrigal, which validates the Chinese company's research and development know-how. The pharmaceutical company's sales could grow to CNY13 billion in 2040 from CNY176 million in 2025, they add. Macquarie Capital starts coverage of Ribo with an outperform rating and HK$97.30 target price. Shares last closed 1.5% higher at HK$71.10.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","06938","BK1161","TISI"],"gpt_icon":0},{"id":"2611200811","title":"Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2611200811","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611200811?lang=en_us&edition=fundamental","pubTime":"2026-02-16 00:29","pubTimestamp":1771172947,"startTime":"0","endTime":"0","summary":"Why Suzhou Ribo Life Science Is Drawing Investor Attention\nSuzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline.\nSee our latest analysis for Suzhou Ribo Life Science.\nThe latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1159287871","title":"RIBOLIFE-B (06938) Issues 4.7414 Million H Shares Following Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1159287871","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159287871?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:17","pubTimestamp":1770877042,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on February 10, 2026, the company issued and allotted 4.7414 million H shares as a result of the full exercise of the over-allotment option.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"gpt_icon":0},{"id":"1141269694","title":"Suzhou Ribo (06938) Increases Issued H Shares Following Over-Allotment Option Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1141269694","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141269694?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:01","pubTimestamp":1770876090,"startTime":"0","endTime":"0","summary":"According to the latest disclosure dated 12 February 2026, Suzhou Ribo Life Science Co., Ltd. (stock code: 06938) reported a share issuance resulting from the full exercise of an over-allotment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1112861737","title":"SASAC Urges Central Enterprises to Boost Computing Power Investment; SanDisk Shares Surge Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112861737","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112861737?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:09","pubTimestamp":1770854983,"startTime":"0","endTime":"0","summary":"The State Council has issued the \"Implementation Opinions on Improving the National Unified Electricity Market System,\" setting targets to establish a basic framework by 2030 and fully complete the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","LU0278937759.USD","09899","BK4585","06938","LU0231459107.USD","SNDK","BK1161","VXUS","IE0009570106.USD","BK1615","VT","BK1128","BK4588"],"gpt_icon":0},{"id":"2610493993","title":"Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610493993?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:25","pubTimestamp":1770809124,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA5TLHS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK1161","BK4139","06938","BK4588","MDGL"],"gpt_icon":0},{"id":"1111063693","title":"Suzhou Ribo (6938) and Madrigal Sign Exclusive Worldwide Licensing Deal for Pre-Clinical siRNA Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1111063693","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111063693?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:20","pubTimestamp":1770805243,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (6938) and its subsidiary Ribocure Pharmaceuticals AB reached an exclusive worldwide licensing agreement on February 11, 2026, with Madrigal Pharmaceuticals, Inc....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2610933985","title":"Madrigal, Suzhou Ribo in license deal for liver‑disease programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933985","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933985?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:10","pubTimestamp":1770804632,"startTime":"0","endTime":"0","summary":"Madrigal, Suzhou Ribo in license deal for liverdisease programsFeb 11  - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has signed an exclusive global license agreement with China-based Suzhou Ribo Life Science 6938.HK and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA programs to treat a type of liver disease.   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","BK4585","06938","MDGL","BK4588"],"gpt_icon":0},{"id":"1132391081","title":"RIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1132391081","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132391081?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:09","pubTimestamp":1770804560,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2610933517","title":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933517","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933517?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:09","pubTimestamp":1770804556,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With MadrigalFeb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK4588","MDGL","BK4585","BK4139","BK1161"],"gpt_icon":0},{"id":"2610333309","title":"Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science","url":"https://stock-news.laohu8.com/highlight/detail?id=2610333309","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610333309?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:03","pubTimestamp":1770804218,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc. has entered into an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA  programs. This partnership will expand Madrigal’s pipeline for metabolic dysfunction-associated steatohepatitis  by advancing next-generation siRNA therapies that target genes implicated in the disease. The collaboration aims to develop precision gene-silencing treatments to address unmet needs in MASH, complementing Madrigal’s foundational therapy, Rezdiffra.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on February 11, 2026, and i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbLh597:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938","MDGL","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2610393801","title":"Suzhou Ribo Life Science - to Receive $60 Mln Upfront Payment, up to $4.4 Bln Total","url":"https://stock-news.laohu8.com/highlight/detail?id=2610393801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610393801?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:00","pubTimestamp":1770804041,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2610338509","title":"Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2610338509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610338509?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:00","pubTimestamp":1770804041,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK4139","MDGL","BK4588","BK4585","BK1161"],"gpt_icon":0},{"id":"2610293801","title":"Suzhou Ribo Life Science Co Ltd -  Exclusive Worldwide Licensing Agreement With Madrigal for Several Sirna Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2610293801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610293801?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:00","pubTimestamp":1770804041,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1108811690","title":"RIBOLIFE-B Surges Over 5% as RBD5044 Receives Implied Approval for Phase II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1108811690","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108811690?lang=en_us&edition=fundamental","pubTime":"2026-02-10 11:48","pubTimestamp":1770695297,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) rose more than 5%, reaching a gain of 5.62% to HK$72.45 by the time of writing, with a turnover of HK$6.483 million. The increase follows the company's recent announcement that its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK4588","VXUS","BK4585","BK1161","VT"],"gpt_icon":0},{"id":"2609534413","title":"Suzhou Ribo Life Science Raises HK$262 Million From Full Exercise of Overallotment Option in Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2609534413","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609534413?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:15","pubTimestamp":1770344156,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  said its underwriters fully exercised the overallotment option of its Hong Kong listing, and the stabilization period of its initial public offering ended on Thursday, Feb. 5, according to a same-day filing with the Hong Kong bourse.Shares of the life sciences company fell over 3% in morning trade Friday.The firm issued 4.7 million H shares at HK$57.97 apiece for additional net proceeds of HK$262.5 million.The overallotment option was exercised after an equal number of shares were over-allocated in the international portion of the IPO.The IPO's underwriters did not purchase or sell shares from the open market during the stabilization period.The number of shares held by the public after the exercise of the overallotment option complied with Hong Kong's listing requirements, the firm said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"1157587374","title":"Suzhou Ribo Life Science (6938) Announces Full Exercise of Over-Allotment Option and End of Stabilization Period","url":"https://stock-news.laohu8.com/highlight/detail?id=1157587374","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157587374?lang=en_us&edition=fundamental","pubTime":"2026-02-05 23:04","pubTimestamp":1770303861,"startTime":"0","endTime":"0","summary":"According to the announcement, Suzhou Ribo Life Science Co., Ltd. (Stock Code: 6938) has fully exercised the Over-allotment Option in its Global Offering. On February 5, 2026, the Overall...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1111109349","title":"RIBOLIFE-B Fully Exercises Over-Allotment Option as Stabilization Period Concludes","url":"https://stock-news.laohu8.com/highlight/detail?id=1111109349","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111109349?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:40","pubTimestamp":1770302418,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) has announced that the overall coordinators, acting on behalf of the international underwriters, fully exercised the over-allotment option described in the prospectus on Thursday,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":-0.0921},{"period":"3month","weight":0.2334},{"period":"ytd","weight":0.2334}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0},{"period":"3month","weight":0.0316},{"period":"6month","weight":0.0673},{"period":"1year","weight":0.162},{"period":"ytd","weight":0.0443}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company’s main business is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.","exchange":"SEHK","name":"RIBOLIFE-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RIBOLIFE-B(06938) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RIBOLIFE-B,06938,RIBOLIFE-B股票,RIBOLIFE-B股票老虎,RIBOLIFE-B股票老虎国际,RIBOLIFE-B行情,RIBOLIFE-B股票行情,RIBOLIFE-B股价,RIBOLIFE-B股市,RIBOLIFE-B股票价格,RIBOLIFE-B股票交易,RIBOLIFE-B股票购买,RIBOLIFE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RIBOLIFE-B(06938) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}